DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 10,917 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total value of $1,558,838.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Andrew K. Balo also recently made the following trade(s):
- On Friday, December 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $121.23, for a total value of $606,150.00.
Shares of NASDAQ:DXCM opened at $146.85 on Friday. DexCom, Inc. has a 12 month low of $64.15 and a 12 month high of $156.16. The company has a market cap of $12.94 billion, a P/E ratio of 489.50 and a beta of 0.78. The company has a current ratio of 7.64, a quick ratio of 7.32 and a debt-to-equity ratio of 1.52.
Large investors have recently made changes to their positions in the stock. Laurel Wealth Advisors LLC bought a new stake in DexCom during the fourth quarter worth approximately $26,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in DexCom during the fourth quarter worth approximately $33,000. First Hawaiian Bank raised its holdings in DexCom by 75.6% during the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after purchasing an additional 170 shares in the last quarter. Bremer Trust National Association bought a new stake in DexCom during the fourth quarter worth approximately $49,000. Finally, LS Investment Advisors LLC bought a new stake in DexCom during the fourth quarter worth approximately $67,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on the company. Cowen lifted their target price on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Canaccord Genuity lifted their price target on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, February 22nd. Morgan Stanley lifted their price target on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, February 25th. Piper Jaffray Companies lifted their price target on DexCom to $165.00 and gave the company an “overweight” rating in a report on Wednesday, January 9th. Finally, UBS Group lifted their price target on DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, January 8th. Seven analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $149.53.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://dakotafinancialnews.com/2019/03/15/insider-selling-dexcom-inc-dxcm-insider-sells-10917-shares-of-stock.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: What is a stock buyback?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.